Fig. 5
EVT901 treatment reduced CCR2+ monocytes in the injured brain and circulation and reduced tissue damage at 7 days after TBI. a Blood was obtained from CCR2+/RFP Tg mice at 7 days after TBI with or without EVT901. One-way ANOVA showed that there was a significant difference between vehicle and EVT901 after injury (F 1,8 = 8.12, p = 0.03, η 2 = 0.58, power = 0.66) (n = 3/group). b Brain sections from CCR2+/RFP Tg mice were obtained from the lesion area as shown (region of interest (ROI), from 1.5 mm anterior to 1.5 mm posterior of bregma). c CCR2+/RFP cells were observed predominantly in the injured area. d RFP-positive signal was quantified and the proportional area (P.A. = the area of CCR2-RFP+ signal/total area × 100) is shown. CCR2-RFP-positive signal was highly increased after TBI, and EVT901 treatment significantly reduced it. ANOVA showed a significant effect of side (F 1,28 = 35.03, p < 0.001, η 2 = 0.83, power = 0.999), condition (F 2,7 = 10.97, p = 0.007, η 2 = 0.758, power = 0.922), side × condition (F 2,28 = 7.81, p < 0.02, η 2 = 0.69, p = 0.81), and section (F 4,28 = 2.83, p < 0.043, η 2 = 0.288, power = 0.695). e EVT901 increased the spared tissue area after TBI. One-way ANOVA showed a significant main effect of condition (F 2,7 = 12.00, p = 0.005, η 2 = 0.774, power = 0.942). Tukey’s post hoc test comparing TBI-vehicle vs TBI-EVT901 was significant (*p = 0.0374), and comparing UN vs TBI-vehicle was also significant (†p = 0.005). Scale bars in C = 1000 μm (left) and 100 μm (right). (n = 4/group)